Perrigo (PRGO) Q2 EPS Rises 7.5%

Perrigo (NYSE:PRGO), a major supplier of over-the-counter (OTC) self-care products across North America and Europe, released its Q2 FY2025 financial results on August 6, 2025. The company posted adjusted earnings per share of $0.57, missing the consensus non-GAAP EPS estimate of $0.59. Net sales (GAAP) came in at $1.06 billion, falling short of the $1,082.73 million analyst target (GAAP revenue) and dropping 0.9% year-over-year on a GAAP basis. Gross margin and operating margin saw notable declines, particularly driven by operational challenges in infant formula and lower absorption in select product lines. Despite the revenue and earnings misses, management reaffirmed full-year FY2025 adjusted EPS guidance of $2.90 to $3.10, cautioning that reported and organic net sales growth would likely be at the lower end of previous ranges for FY2025. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Perrigo is a global consumer self-care company, mainly known for its wide range of OTC health and wellness products. Its portfolio spans segments including nutrition, women's health, pain relief, oral care, digestive health, and skin care. The company's diverse lineup covers both store brands and several international branded products, making it one of North America's leading store-brand suppliers and a strong name in Europe with brands like Compeed (wound care patches) and ellaOne (emergency contraception pill).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool